Clinical trial PALLAS
PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Oui |
| Sponsor | ABCSG |
| EudraCT Identifier | 2014-005181-30 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02513394 |
| Inclusion criteria | ER+/PR+/HER2-. Adjuvant. Palbociclib |
| Last update |